Germany’s Boehringer Ingelheim is to make a bank of its molecules available to scientists in a bid to encourage open innovation during the COVID-19 pandemic, when many scientists are working from home.
The family-owned company has dubbed its new crowdsourcing platform opnMe, and aims to set new standards of collaboration within the scientific community.
By improving cooperation and collaboration, Boehringer aims to accelerate research projects and improve knowledge about diseases for which there are few available treatments.
Image: https://pharmaphorum.com
